|会社名||AbbVie Inc （ABBV アッヴィ）|
|業種||医薬品 医療関連（Health Care）|
|概要||事業概要 アッヴィ(AbbVie Inc.)は研究型バイオ医薬品会社である。同社は各種医薬品の発見・開発・製造・販売に従事する。同社の製品はリウマチ学、胃腸病学と皮膚科学等の慢性自己免疫疾患、血液癌を含む腫瘍学、C型肝炎ウイルス（HCV）とヒト免疫不全ウイルス（HIV）を含むウイルス学、パーキンソン病と多発性硬化症等の神経学的障害、甲状腺疾患と嚢胞性線維症関連合併症を含む代謝性疾患、並びに他の健康状態の治療のために使用される。同社はHUMIRA（アダリムマブ）、腫瘍学製品、ウイルス学、追加のウイルス学製品、代謝またはホルモン製品、内分泌学製品、並びにDuopaおよびDuodopa（カルビドパおよびレボドパ）、麻酔薬およびZINBRYTA（ダクリズマブ）を含む他の製品を提供する。 アッヴィは米国の研究開発型バイオ医薬品企業。主にC型肝炎、神経学、免疫学、腫瘍学、慢性腎疾患および女性の疾患などの分野における医薬品の開発に取り組む。アボット・ラボラトリ―ズの研究開発医薬品部門の分離独立に伴い2013年度に設立。主力製品はリウマチ性関節炎や乾癬治療薬｢ヒュミラ｣など。本社はイリノイ州ノ―ス・シカゴ。 AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. The Company strives to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.|
|代表者氏名||Richard A. Gonzalez|
|代表者役職名||Chairman of the Board Chief Executive Officer|
|決算概要||決算概要 BRIEF: For the fiscal year ended 31 December 2018 AbbVie Inc revenues increased 16% to $32.75B. Net income applicable to common stockholders excluding extraordinary items increased 1% to $5.74B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was partially offset by Research and development - Balanci increase from $4.82B to $10.16B (expense) Selling.|
AbbVie to Present at the Barclays Global Healthcare Conference 2023/03/08 13:00:00 AbbVie
NORTH CHICAGO, Ill. , March. 8, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Barclays Global Healthcare Conference on Wednesday, March 15, 2023 . Robert A. Michael , vice chairman and president, Scott Reents , executive vice president, chief financial officer, Jeffrey R.
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason 2023/03/08 00:34:06 Benzinga
The Health Care Select Sector SPDR Fund (NYSEARCA: XLV), heavily tilted towards mega-caps, lost around 5.25% over the last month, with substantial companies reporting annual earnings. Shares of Health Care Select Sector SPDR Fund opened at $129.26 on Monday, with a twelve-month low of $118.75 and a twelve-month high of $143.42. YTD shares lost 6.54%. Top holding companies Merck & Co Inc (NYSE: MRK ), AbbVie Inc (NYSE: ABBV ), Eli Lilly And Co (NYSE: LLY ), Thermo Fisher … Full story available on Benzinga.com
A massive haul for AbbVie''s CEO under new pay disclosure rules 2023/03/07 23:00:15 Crain''s Chicago
"Compensation actually paid" to Richard Gonzalez topped $67 million, more than double his pay calculated the old way.
AbbVie Inc. (ABBV) Cowen 43rd Annual Healthcare Conference (Transcript) 2023/03/07 17:48:04 Seeking Alpha
AbbVie Inc. (NYSE:NYSE:ABBV) Cowen 43rd Annual Healthcare Conference Call March 7, 2023 9:10 AM ETCompany ParticipantsRoopal Thakkar - Senior Vice President, Development and Regulatory…
7 Dividend Kings to Buy for an Uncertain Market Environment 2023/03/06 21:51:35 InvestorPlace
Though the term dividend aristocrats generate plenty of interest for the underlying elite status, another even more rarefied category exists called dividend kings to buy. Rather than 25 years of consecutive payout growth, the kings command at least 50 years. As we head into uncertain times, investors should pay close attention to this rare group of enterprises. Fundamentally, of course, companies that can afford to provide passive income to their stakeholders tend to be deeply established businesses. Should unexpected turbulence hit the market, they’re likelier to ride out the turmoil compared to growth-centric organizations. Therefore, dividend kings to buy deserve serious consideration for your portfolio. In addition, these elites of elite firms will want to keep the trend going at any cost. Naturally, you don’t want to be the person responsible for a 50-plus-year track record being broken. Thus, you’re in reasonably good hands with these dividend kings to buy. ABBV AbbVie $155.28 CL Colgate-Palmolive $73.29 PG Procter & Gamble $140.35 NWN Northwest Natural $47.41 KO Coca-Cola $60.36 SYY SYSCO $76.35 JNJ Johnson & Johnson $155.56 AbbVie (ABBV) Source: Sisacorn / Shutterstock.com A top-flight pharmaceutical firm, AbbVie (NYSE: ABBV ) ranks among the most intriguing dividend kings to buy.
Top 5 4th Quarter Trades of PARAGON FINANCIAL PARTNERS, INC. 2023/02/03 04:00:10 GuruFocus
Related Stocks: ETV , ABBV , XOM , DFAT , JPM ,
The 3 Most Undervalued Penny Stocks to Buy in February 2023 2023/02/02 16:28:18 InvestorPlace
If finding undervalued stocks is good, then finding undervalued penny stocks is even better. That’s because, with penny stocks, investors’ capital appreciation upside potential is amplified. Of course, risks are also amplified, making such companies often all-or-nothing bets. Penny stocks, which for this article I define as stocks trading for less than $5, are cheap for a reason. Many of these companies are not profitable. Some are even in the pre-revenue stage. Not surprisingly, many penny stocks were hit hard in 2022 as investors moved away from risk-on assets. It appears one of the reasons investors are enjoying some relief to start 2023 is the “January Effect.” Stock prices have mostly climbed to start the year, with bullish expectations around what the Federal Reserve will do sparking interest in riskier assets. Accordingly, this means that now could be the best time to start speculating on a few high-quality penny stocks. If such a high-risk high-reward investing style suits you, here are three such companies to consider right now.
Top 5 4th Quarter Trades of Guinness Asset Management LTD 2023/02/02 16:00:08 GuruFocus
Related Stocks: VFC , CME , ABBV , AFL , AVGO ,
United States: Amgen Launches AMJEVITA—First Biosimilar To HUMIRA In The United States - Goodwin Procter LLP 2023/02/02 15:58:39 Mondaq
Amgen announced today the launch of AMJEVITA (adalimumab-atto), a biosimilar to AbbVie''s HUMIRA (adalimumab), in the United States. AMJEVITA was the first HUMIRA biosimilar approved…
This stocks will boost Up Your investment: SmileDirectClub, Inc. (NASDAQ:SDC 11.65%), AbbVie Inc. (NYSE:ABBV -0.78%) 2023/02/02 00:57:49 Stock Equity
SDC has seen its SMA50 which is now 25.25%. In looking the SMA 200 we see that the stock has seen a -38.92%. ABBV has seen its SMA50 which is … The post This stocks will boost Up Your investment: SmileDirectClub, Inc. (NASDAQ:SDC 11.65%), AbbVie Inc. (NYSE:ABBV -0.78%) appeared first on Stocks Equity .
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AbbVie and Twitter and Encourages Investors to Contact the Firm 2022/04/18 01:00:00 GlobeNewswire
NEW YORK, April 17, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of AbbVie, Inc. (NYSE: ABBV) and Twitter, Inc. (NYSE: TWTR). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Gastrointestinal Diseases Therapeutics Market to record USD 22.82 Bn growth | Evolving Opportunities with Abbott Laboratories and AbbVie Inc. | Technavio 2022/04/15 10:45:00 PR Newswire
NEW YORK, April 15, 2022 /PRNewswire/ -- The global gastrointestinal diseases therapeutics market size is expected to increase by USD 22.82 billion between 2019 and 2024, and the growth momentum is expected to accelerate at a CAGR of 9% during the forecast period. The report provides a…
Global Small-cell Lung Cancer Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight 2022/04/14 17:00:00 Benzinga
Las Vegas, USA, April 14, 2022 (GLOBE NEWSWIRE) -- Global Small-cell Lung Cancer Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight Small-cell Lung Cancer Pipeline constitutes 100+ key companies continuously working towards developing 100+ Small-cell Lung Cancer treatment therapies, analyzes DelveInsight DelveInsight''s Small-cell Lung Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Small-cell Lung Cancer pipeline domain. Some of the essential takeaways from the Small-cell Lung Cancer Pipeline report: DelveInsight''s Small-cell Lung Cancer Pipeline analysis depicts a robust space with 100+ active players working to develop 100+ Small-cell Lung Cancer treatment pipeline therapies. Some of the key Small-cell Lung Cancer companies proactively working to develop potential drug candidates to improve the Small-cell Lung Cancer treatment scenario include Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, Advanced Accelerator Applications, Trillium Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Aileron Therapeutics, Ipsen, Celgene, Lee''s Pharmaceutical Limited, AbbVie, Chipscreen Biosciences, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, Amgen, Bristol-Myers Squibb, Genentech, Sorrento Therapeutics, DAIICHI SANKYO COMPANY, BioNTech, Harpoon Therapeutics, Genprex, Inc., Tarveda Therapeutics, Taizhou HoudeAoke Biomedical Co., Ltd., BeiGene, HaiHe Biopharma, Kartos Therapeutics, Inc., Boehringer Ingelheim, Y-mAbs Therapeutics, CStone Pharmaceuticals, EpicentRx, Inc., Pfizer, Mologen, Cybrexa Therapeutics, and many others.
AbbVie - Genmab Post Epcoritamab Data From Early-Stage Blood Cancer Study 2022/04/14 10:09:00 Benzinga
Genmab A/S (NASDAQ: GMAB ) and AbbVie Inc (NYSE: ABBV ) announced topline results from the first cohort of the EPCORE NHL-1 phase 1/2 trial of epcoritamab (DuoBody-CD3xCD20). Epcoritamab is an investigational IgG1-bispecific antibody created using Genmab''s DuoBody technology designed to direct cytotoxic T cells selectively to tumors to elicit an immune response towards malignant cells. The study cohort … Full story available on Benzinga.com
US stock market closes higher, Dow Jones gains 1.01% 2022/04/14 03:21:49 InstaForex
At the close on the New York Stock Exchange, the Dow Jones rose 1.01%, the S&P 500 index rose 1.12%, the NASDAQ Composite index rose 2.03%. The leading gainer among the components of the Dow Jones index today was Boeing Co, which gained 6.59 points or 3.74% to close at 182.87. Walmart Inc rose 3.99 points or 2.60% to close at 157.22. American Express Company rose 4.05 points or 2.31% to close at 179.59. The biggest losers were JPMorgan Chase & Co, which shed 4.24 points or 3.22% to end the session at 127.30. The Travelers Companies Inc rose 1.23 points (0.67%) to close at 183.71, while 3M Company gained 0.08 points (0.05%) to close at 148. .66. Leading gainers among the S&P 500 index components in today''s trading were American Airlines Group, which rose 10.62% to 18.95, Gap Inc, which gained 8.23% to close at 14.46, and shares of Host Hotels & Resorts Inc, which rose 8.12% to end the session at 19.70. The biggest losers were AbbVie Inc, which shed 4.19% to close at 158.95. PayPal Holdings Inc fell 2.85% to 105.17.
関連キーワード （医薬品 米国株 ABBV アッヴィ ABBV ）